Loss to Followup in HIV-Infected Patients from Asia-Pacific Region: Results from TAHOD

Table 2

Patient characteristics.

Total	3626
Characteristics	Number	%
Sex
Male	2567	71
Female	1059	29
Current age (years)
≤35	1383	38
36–45	1449	40
46+	794	22
Reported exposure
Heterosexual contact	2337	64
Homosexual contact	749	21
Injecting drug use	263	7
Other/unknown	277	8
Ethnicity
Chinese	989	27
Indian	390	11
Thai	933	26
Other/unknown	1314	36
Baseline CD4 count (cells/μl.)
≤100	239	7
101–200	406	11
201+	2531	70
Missing	450	12
Baseline HIV RNA (copies/ml)
≤500	1482	41
501+	379	10
Missing	1765	49
CDC disease stage at baseline
Stage A	1621	45
Stage B	321	9
Stage C	1684	46
Tuberculosis diagnosis at baseline
No	2758	76
Yes	868	24
Time since HIV infection (years)
≤5	2295	63
6+	1246	34
Missing	85	2
Hepatitis B infection
No	2297	63
Yes	257	7
Not tested	1072	30
Hepatitis C infection
No	2007	55
Yes	324	9
Not tested	1295	36
Anemia at baseline
No	2480	68
Yes	597	16
Haemoglobin not tested	567	16
Antiretroviral treatment at baseline
3 + (NRTI + NNRTI)	2224	61
3 + (NRTI + PI)	744	21
No/mono/double drug	583	16
3 + (other combination)	75	2

Anemia: haemoglobin <13 g/dl (male), <11 g/dl (female); NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: nonnucleoside reverse transcriptase inhibitor; PI: protease inhibitor.